Effect of Vitamin B12 supplementation on glycemic control, albuminuria and peripheral neuropathy in diabetes mellitus patients - a cross sectional study.
{"title":"Effect of Vitamin B12 supplementation on glycemic control, albuminuria and peripheral neuropathy in diabetes mellitus patients - a cross sectional study.","authors":"Rahul Kumar, Pinky Garg, Mansi Modi, Deepak Das, Harshvardan Singh","doi":"10.1515/hmbci-2026-0016","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Type 2 Diabetes Mellitus (T2DM) is a global health challenge linked to microvascular complications like neuropathy and nephropathy. Metformin, first-line therapy, is associated with Vitamin B12 deficiency, potentially worsening neurological outcomes. This study assessed B12 supplementation's association with glycemic control, albuminuria, and peripheral neuropathy.</p><p><strong>Methods: </strong>A cross-sectional study at Hindu Rao Hospital, New Delhi, included 151 T2DM patients (≥30 years) on B12 supplementation. Serum B12, HbA<sub>1c</sub>, and urinary albumin-creatinine ratio (ACR) were measured. Neuropathy was evaluated using the Diabetic Neuropathy Symptom (DNS) score. Analysis used SPSS v23; (p<0.05) was significant.</p><p><strong>Results: </strong>Mean age was 50.79 ± 9.60 years (63.6 % female). Neuropathy prevalence (DNS≥1) was 76.8 %. Mean B12 was 452.25 ± 360.86 pg/mL. B12 levels differed significantly across glycemic groups (p<0.001), highest in HbA<sub>1c</sub>>8.5 %. Neuropathy associated with B12 levels (p=0.027) and oral hypoglycemic use (p=0.010). Logistic regression showed higher B12 paradoxically linked to neuropathy (AOR=1.003; (p=0.023)). No ACR difference (p=0.879).</p><p><strong>Conclusions: </strong>B12 shows complex ties to neuropathy and glycemic control in supplemented T2DM patients. Elevated serum levels may not indicate functional adequacy; monitoring functional markers like homocysteine or methylmalonic acid is recommended.</p>","PeriodicalId":13224,"journal":{"name":"Hormone Molecular Biology and Clinical Investigation","volume":" ","pages":"115-122"},"PeriodicalIF":1.9000,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Molecular Biology and Clinical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/hmbci-2026-0016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Type 2 Diabetes Mellitus (T2DM) is a global health challenge linked to microvascular complications like neuropathy and nephropathy. Metformin, first-line therapy, is associated with Vitamin B12 deficiency, potentially worsening neurological outcomes. This study assessed B12 supplementation's association with glycemic control, albuminuria, and peripheral neuropathy.
Methods: A cross-sectional study at Hindu Rao Hospital, New Delhi, included 151 T2DM patients (≥30 years) on B12 supplementation. Serum B12, HbA1c, and urinary albumin-creatinine ratio (ACR) were measured. Neuropathy was evaluated using the Diabetic Neuropathy Symptom (DNS) score. Analysis used SPSS v23; (p<0.05) was significant.
Results: Mean age was 50.79 ± 9.60 years (63.6 % female). Neuropathy prevalence (DNS≥1) was 76.8 %. Mean B12 was 452.25 ± 360.86 pg/mL. B12 levels differed significantly across glycemic groups (p<0.001), highest in HbA1c>8.5 %. Neuropathy associated with B12 levels (p=0.027) and oral hypoglycemic use (p=0.010). Logistic regression showed higher B12 paradoxically linked to neuropathy (AOR=1.003; (p=0.023)). No ACR difference (p=0.879).
Conclusions: B12 shows complex ties to neuropathy and glycemic control in supplemented T2DM patients. Elevated serum levels may not indicate functional adequacy; monitoring functional markers like homocysteine or methylmalonic acid is recommended.
期刊介绍:
Hormone Molecular Biology and Clinical Investigation (HMBCI) is dedicated to the provision of basic data on molecular aspects of hormones in physiology and pathophysiology. The journal covers the treatment of major diseases, such as endocrine cancers (breast, prostate, endometrium, ovary), renal and lymphoid carcinoma, hypertension, cardiovascular systems, osteoporosis, hormone deficiency in menopause and andropause, obesity, diabetes, brain and related diseases, metabolic syndrome, sexual dysfunction, fetal and pregnancy diseases, as well as the treatment of dysfunctions and deficiencies. HMBCI covers new data on the different steps and factors involved in the mechanism of hormone action. It will equally examine the relation of hormones with the immune system and its environment, as well as new developments in hormone measurements. HMBCI is a blind peer reviewed journal and publishes in English: Original articles, Reviews, Mini Reviews, Short Communications, Case Reports, Letters to the Editor and Opinion papers. Ahead-of-print publishing ensures faster processing of fully proof-read, DOI-citable articles.